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Even as genetic studies identify alleles that influence human disease 
susceptibility, it remains challenging to understand their functional 
significance and how they contribute to disease phenotypes.  Here we 
describe an approach to translate discoveries from human genetics into 
functional and therapeutic hypotheses by relating human genetic variation 
to small-molecule sensitivities. We use small-molecule probes modulating 
a breadth of targets and processes to reveal disease allele-dependent 
sensitivities, using cells from multiple individuals with an extreme form of 
diabetes (MODY1, caused by mutation in the orphan nuclear receptor 
HNF4Į). This approach enabled the discovery of small molecules that show 
mechanistically revealing and therapeutically relevant interactions with 
HNF4Į in both lymphoblasts and pancreatic ȕ cells, including compounds 
that physically interact with HNF4Į. Compounds including FDA-approved 
drugs were identified that favorably modulate a critical disease phenotype, 
insulin secretion from ȕ cells. This method may suggest therapeutic 
hypotheses for other non-blood disorders.  
 
\body 
Genetic variants that influence susceptibility to disease have been identified for 
many diseases. Reproducing human genetic lesions in cellular or animal models 
for functional studies can be challenging, particularly when the causal variants 
are not known or fall outside coding regions. Furthermore, for genetically 
complex diseases such as type-2 diabetes, multiple genes influence an 
individualﾒ’s risk of disease. The use of patient-derived cells allows disease alleles 
to be studied in their native genetic background, but is often hampered by limited  
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access to traditional disease-related cell types (such as pancreatic ȕ cells for 
diabetes). In genetically tractable model organisms, genetic interaction screens 
provide a powerful, systematic method to reveal genes and pathways that 
interact with a given mutation (1-3); similarly, in genetically defined cell lines, the 
concept of synthetic lethality has been used to identify compounds that 
selectively kill cells expressing an oncogene (4).  
 
Here, we apply the logic of genetic interaction screens to study human disease 
alleles in cells from individual patients, using small-molecule probes as a source 
of systematic perturbation (particularly marketed drugs and bioactives with 
characterized activity).  To discover small molecule-gene interactions, we screen 
for small molecules that induce distinct cellular phenotypes depending on the 
presence or absence of a disease mutation (Fig. 1).  This implies that the small 
molecules (or their protein targets) functionally interact with the disease mutation, 
and identifies nodes where cellular pathways intersect with a disease gene.  Both 
directions of small molecule-induced effects could potentially be informative (i.e., 
small-molecule-induced assay measurements greater in either mutant or wild-
type cells).  Similarly, small molecule-gene interactions can potentially be 
identified using cell-based measurements that reflect specific biological 
pathways, or broader measures of cell function or viability; different 
measurements would likely identify partially overlapping subsets of interactions. 
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Type-2 diabetes is a genetically heterogenous disease; monogenic forms 
comprise approximately 2-5% of cases but may shed light on the pathogenesis 
or treatment of the common form of type-2 diabetes. Maturity Onset Diabetes of 
the Young type 1 (MODY1) is an extreme form of diabetes characterized by early 
onset diabetes (often before age 25) due to impaired pancreatic insulin secretion 
(5-7). The causal mutation is in the orphan nuclear hormone receptor HNF4Į, a 
transcription factor that plays wide-ranging roles in embryonic development, and 
the function of liver, pancreas and other tissues. HNF4Į binds to upstream 
sequences of hundreds of genes involved in glucose, lipid, cholesterol, amino 
acid and drug metabolism (8-10). Two different conditional knockouts of HNF4Į 
in   cells yielded conflicting phenotypes:  while both knockout models showed 
impaired insulin secretion in response to glucose challenge (11, 12), one model 
also unexpectedly showed elevated resting insulin levels with associated 
hypoglycemia (12), highlighting our incomplete understanding of the physiologic 
effects of HNF4Į mutation.  
 
In this study, we develop an approach to identify small molecule-gene 
interactions in MODY1 diabetes, using patient-derived lymphoblast cell lines 
(LCLs, derived from B-lymphocytes) as a surrogate cell model, and a 
luminescence-based assay for cellular ATP as the cell measurement.  LCLs (and 
other cells derived from the peripheral circulation) are easily accessible from 
patient cohorts, but their utility as cell models for functional studies of non-blood  
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disorders is not widely established.  Gene expression data from LCLs have been 
used to study DNA variants that influence gene expression (13) as well as the 
mechanism of genetic variants implicated in asthma (14) and systemic lupus 
erythematosus (SLE) (15).  We identify multiple small molecules that functionally 
interact with HNF4Į in LCLs, including fatty acids that physically interact with 
HNF4Į.  Several of these small molecule-gene interactions are preserved in 
murine pancreatic   cells, a canonical cell model for diabetes studies.  
Furthermore, our approach identifies compounds that modulate a key disease 
phenotype, insulin secretion from   cells.  These results suggest that systematic 
identification of synthetic interactions between small molecules and disease 
alleles can provide a functional context for disease-causing alleles, and suggest 
novel therapeutic hypotheses. 
 
RESULTS 
Small molecule-disease allele interaction screen in patient LCLs 
We studied LCLs from 18 members of a MODY1 family (10 with diabetes and 8 
without; Fig. 2) in which affected members possess a Q268X nonsense mutation 
(16). This mutation truncates the ligand binding domain and leads to impaired 
DNA binding, abnormal cellular trafficking, and loss of transcriptional activity (8, 
17). Sequencing and RT-PCR confirmed the presence of a heterozygous C-to-T 
substitution in codon 268 exclusively in the diabetic subjects, and low levels of 
HNF4Į expression. LCLs were treated with 3,973 clinically used drugs and small     6
molecules whose activities have been previously characterized. The effects of 
small-molecule treatments were measured using a luminescence assay for 
cellular ATP content, chosen as a viability assay, and also for reasons related to 
diabetic metabolism: type-2 diabetes has been associated with impairments in 
oxidative phosphorylation (18), and ATP concentrations in pancreatic islets are a 
key sensor during insulin secretion (19). ATP assay values were converted to a 
Z-score (multiples of the standard deviation of the distribution of control wells in 
the same cell line) (20). The assay was highly reproducible with a coefficient of 
variation routinely <10% (Supplemental Table S1). Each small-molecule 
treatment was performed in duplicate at a single concentration.   
 
To assess the extent to which each small molecule induced different assay Z-
scores in mutant vs. wild-type LCLs, we calculated a signal-to-noise statistic 
(S2N): S2N = (ȝMutant ﾖ– ȝWT) / (ıMutant + ıWT) (21). (ȝMutant and ıMutant are the mean 
and standard deviation, respectively, of the ATP assay Z-scores averaged across 
all mutant cell lines; ȝWT and ıWT are the corresponding values across wild-type 
cell lines.) The magnitude of S2N is greatest (either positive or negative in sign) 
for small molecules that best discriminate between mutant vs. wild-type LCLs in 
our assay (Figs. 3a and 3b, Supplemental Dataset S1); this suggests a small 
molecule-gene interaction, such as a physical association or functional 
interaction between HNF4Į and the small molecule (or its target protein).   
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Compound-set-enrichment-analysis identifies small molecules with 
disease-allele dependent effects 
While many small molecules with the most positive or most negative S2N had p 
values < 0.05 (calculated by permutation of mutant and wild-type class labels; 
Supplemental Dataset S1), after correcting for multiple hypothesis testing, 
individual compounds did not meet statistical significance. To better identify 
patterns in these data, we tested whether sets of related compounds were 
statistically enriched among the most discriminating compounds, even if the 
discriminating effect of individual compounds was subtle. We curated the 
screened compounds into 141 compound sets (each containing from 3 to 60 
compounds) based on drug class or activity in a common biologic pathway 
(Supplemental Table S2). A weighted Kolmogorov-Smirnov-like statistic 
(normalized enrichment score, NES) was calculated for each compound set that 
reflects the extent to which set members are statistically enriched among 
compounds with the most positive or negative S2N; P-values were calculated by 
randomly permuting mutant vs. wild-type class labels 1000 times (Figures 4a and 
4b). This approach is analytically analogous to gene set enrichment analysis (18, 
22) for gene expression data, and has been used to robustly identify groups of 
genes (e.g., related by virtue of belonging to a common biological process or 
pathway) that are differentially expressed in two cell types.   
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The most highly ranked compound sets from this approach are listed in Table 1 
(compound set members are listed in Supplemental Table S3). These include 
several classes of drugs approved for conditions other than diabetes, as well as 
a subtype of fatty acids (Fig. 4b). Of note, these compound sets scored narrowly 
better than a set comprised of the most widely used therapy for MODY1, the 
insulin secretagogues belonging to the sulfonylurea class (such as glimepiride 
and tolbutamide; NES = 1.27). We verified that previously reported confounders 
of small-molecule treatment in LCLs such as LCL growth rate and EBV copy 
number (23) do not differ in mutant vs. wild-type LCLs (p = 0.59 and 0.26, 
respectively) (Supplemental Fig. S1). We also confirmed that the observed 
variation in small-molecule-induced ATP measurements did not correlate with the 
growth rate of individual LCLs (Supplemental Fig. S2).  
 
A significant fraction of small molecule-gene interactions are preserved 
from LCLs to pancreatic   cells 
Representative members of the compound sets in Table 1 were validated by two 
methods. First, through dose-ranging experiments, we identified concentrations 
at which representative members of a compound set induce distinct ATP 
measurements in mutant vs. wild-type LCLs. Second, we mimicked the HNF4Į 
mutation in MIN6 cells (murine insulinoma cells composed of pancreatic ȕ cells) 
by stably knocking down HNF4Į by lentiviral shRNA infection, and tested  
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whether discriminating compounds also cause distinct ATP measurements in 
HNF4Į knock down vs. control   cells.  
 
Representative individual compounds from compound sets in Table 1 were 
confirmed to induce distinct responses in mutant vs. wild-type LCLs 
(Supplemental Fig. S3). In pancreatic ȕ cells, 4/9 of the representative 
compounds induced distinct ATP measurements in HNF4Į knockdown vs. 
control cells (Table 1; Fig. 5 shows results for these 4 compounds, as well as for 
dexamethasone, a glucocorticoid that did not show an interaction with HNF4Į in 
ȕ cells). These include the Ȧ-6 fatty acid linoleic acid, and several FDA-approved 
drugs: amiloride (a potassium-sparing diuretic that inhibits the epithelial sodium 
channel); propafenone (an anti-arrhythmic drug that inhibits sodium channels as 
well as other ion channels); and simvastatin (an HMG CoA-reductase inhibitor 
used to treat hyperlipidemia) (Fig. 5). These experiments demonstrate that a 
significant portion of small molecule-gene interactions that are elucidated in 
individual patient LCLs are also preserved in pancreatic ȕ cells, a canonical cell 
model for diabetes.  
 
Small molecules that functionally interact with HNF4  modulate insulin 
secretion 
Small molecules that emerge from the screen or their protein targets presumably 
participate in the same or related biological processes as those involving HNF4Į.     10
We hypothesized that some of these proteins (and their associated pathways) 
may help mediate the cellular effects of disease mutations in HNF4Į, and that 
modulation of these proteins may favorably modify disease phenotypes. Because 
MODY1 patients display impaired insulin secretion (24), we tested the small 
molecules identified in our screen for their effects on insulin secretion from 
pancreatic ȕ cells. Several compounds that showed an interaction with HNF4Į 
status in ȕ cells also modulated insulin secretion, and compounds from different 
classes exerted distinct patterns of effect (Fig. 6; Supplemental Table S4). In ȕ 
cells wild-type for HNF4Į, linoleic acid, amiloride, propafenone and simvastatin 
all increased insulin secretion at basal glucose concentrations (2.5 mM); linoleic 
acid and propafenone also increased insulin secretion at elevated glucose (12.5 
mM). Notably, in HNF4Į knockdown cells, linoleic acid, propafenone, and 
amiloride also increased insulin secretion in the presence of low glucose, high 
glucose, or both, respectively; at high glucose concentration, amiloride and 
propafenone restored insulin secretion in HNF4Į knockdown cells to wild-type 
levels (Fig. 6). Simvastatin caused a complex phenotype, stimulating insulin 
secretion at 2.5 mM glucose but inhibiting insulin secretion at 12.5 mM glucose.  
The distinct effects these compounds exert on insulin secretion (e.g., as a 
function of glucose concentration and mutation status; Supplemental Table S4) 
likely reflect both the complexity of insulin secretion physiology and the different 
mechanisms of different compounds.  Overall, these data illustrate that small 
molecule-disease allele interactions can identify compounds that modulate  
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disease-modifying pathways, and exert therapeutically beneficial or adverse 
effects on disease phenotypes.  
 
DISCUSSION 
By studying blood-derived cells from individuals, we have identified novel 
connections between HNF4 , several drugs, cellular ATP, and insulin secretion. 
These connections add a functional framework to the existing vast catalog of 
HNF4  transcriptional targets, and suggest several new mechanistic and 
therapeutic hypotheses. None of the drugs identified in our study have been 
studied in association with MODY1, and none were approved for diabetes-related 
indications. 
 
One of the compounds identified in our screen, linoleic acid, was the 
predominant species bound to HNF4Į (based upon gas chromatography/mass 
spectrometry (GC/MS)) in livers from fed mice or when rat HNF4Į was 
expressed in human cells (25). Furthermore, crystal structures of HNF4Į show a 
mixture of fatty acids spontaneously bound to the ligand-binding pocket (26, 27). 
These reports suggest that the emergence of linoleic acid and related fatty acids 
from our screen likely arises from their physical association with HNF4Į, which 
strongly supports the ability of our method to identify physiologically relevant 
small molecule-gene interactions in cells from individual patients. A physical 
interaction has also been reported between HNF4Į and the glucocorticoid     12
receptor (the target of dexamethasone); the glucocorticoid receptor 
immunoprecipitates with HNF4Į in HeLa cells and human hepatocytes, and 
dexamethasone increases HNF4Į-mediated transcriptional activation (28). 
 
Amiloride inhibits the epithelial sodium channel (SCNN1A/B) and also shows 
activity against Na
+/H
+ exchangers (29). Derivatives of amiloride have been 
reported to increase insulin secretion from ȕ cells in vitro and in vivo (30, 31).  In 
contrast, no association between propafenone and insulin secretion has been 
previously reported. Propafenone inhibits several channels, especially the 
voltage-gated sodium channel SCN5a and the voltage-gated potassium channel 
KCNH2 (29). Propafenone also inhibits ATP-sensitive potassium channel (KATP) 
currents in myocytes (32) and vascular smooth muscle (33), and the delayed 
rectifier channel Kv2.1 in Xenopus oocytes (34). Decreased activity of KATP or 
Kv2.1 in islets increases insulin secretion (19), suggesting that these channels 
may mediate propafenoneﾒ’s effects on insulin secretion. While amiloride and 
propafenone have not been previously studied in the context of HNF4 , SCNN1A 
(encoding the target of amiloride) and KCNJ11 (encoding Kir6.2, a subunit of 
KATP) are among the hundreds of reported transcriptional targets of HNF4  
(though data on the dependence of KCNJ11 expression on HNF4  in vivo are 
conflicting) (10-12).  
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Our data suggest that functional connections relevant to   cell physiology can be 
elucidated from small molecule-gene interactions in a collection of patient-
derived LCLs; the observation that some compounds showed an interaction with 
HNF4Į in LCLs but not ȕ cells may reflect tissue- or species-specific interactions. 
LCLs have also been used as a model cell system for congenital 
hyperinsulinism/hyperammonemia (35), pharmacogenomic studies (36-38), ion 
channel disorders (39) and Huntingtonﾒ’s disease (40). Our approach can easily 
be extended to other diseases and patient-derived cells, including primary 
circulating blood cells, or even induced pluripotent stem cells (iPS); the choice of 
cell model for each disease study will reflect a balance between access to cells 
and disease-relevant physiology.   
 
We have identified small-molecule sensitivities that are dependent on the 
presence of disease alleles in the native context of cells from individual patients. 
This approach can therefore be particularly useful to study disease alleles that 
are not easily studied by traditional genetic methods. By using small molecules 
as a source of targeted perturbations in patient-derived cells, the approach brings 
the logic of model organism genetics to genetically complex human diseases. 
Chemical-genetic interaction screens in patient samples can help discover 
proteins that participate in disease-relevant processes (thus placing the disease 
mutation in a biological context), and equally important, identify small molecules, 
FDA-approved drugs or genes that act as disease modifiers. Biological discovery     14
and clinical translation may be accelerated since a small molecule can be used 
both to elicit the interaction with the disease mutation and to ameliorate disease 
phenotypes. Small-molecule-based genetic interaction screens using patient-
derived blood cells are useful for exploring a highly heritable form of diabetes, 
and may prove useful for functional studies and clinical translation of human 
disease susceptibility alleles discovered through genome-wide association and 
other genetic studies.  
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METHODS 
Lymphoblast cell line (LCL) culture, small molecule screen, and ATP assay 
LCLs were purchased from Coriell Cell Repositories (Camden, NJ; Figure 2), and 
cultured and maintained as previously described (23).  For screening, LCLs were 
thawed from frozen stocks and maintained by diluting them to 100,000-300,000 
cells/ml daily for ~20 days prior to screening. LCLs were plated in 40 µl media at 
a density of 300,000 cells/ml.  100 nl was then pin transferred from compound 
libraries using a CyBi-Well Vario robot (CyBio US, Boston, MA) and plates were 
incubated at 37°C and 5% CO2 for 40 hours.  The CellTiter-Glo (Promega Corp., 
Madison, WI)) assay for cellular ATP was performed as described (23); 
luminescence data was collected on an Analyst HT plate reader (LJL 
Biosystems, Molecular Devices, Sunnyvale, CA). Each library member was 
screened in each LCL line in duplicate.  For the small-molecule screen, LCLs 
from different individuals were screened in random order.   When individual 
compounds were subsequently retested at various doses, LCLs were incubated 
with compounds for 20 hours; each condition (compound dose and cell line) was 
tested in at least six replicates.   
 
Small molecule libraries 
Compounds screened included the following commercially available collections: 
Prestwick Chemical library of marketed drugs (Prestwick Chemical, Illkirch, 
France; 1120 compounds; 2 mg/ml stock concentration); Spectrum Collection of     16
known bioactives, including drugs, tool compounds and natural products 
(MicroSource Discovery Systems, Gaylordsville, CT; 2000 compounds; 10 mM 
stock concentration); ICCB Bioactives collection (Enzo Life Sciences, Plymouth 
Meeting, PA; 480 compounds; variable concentrations); Biomol-NT collection of 
neurotransmitter drugs and bioactives (Enzo Life Sciences, Plymouth Meeting, 
PA; subset of 287 compounds; 10 mM stock concentration); and 86 discretes 
(various sources; 10 mM stock concentration).  
 
Analysis of interaction screen  
Replicate raw luminescence values for each compound library member in each 
cell line  were converted to a Z-score using a standard analytic pipeline (20).  
Calculation of signal-to-noise score (S2N) for each compound across all LCL 
lines, and rank-ordering of compounds for their ability to discriminate LCLs that 
are mutant vs. wild-type at HNF4  was performed using the Comparative Marker 
Selection module of GenePattern (41, 42), a data analysis platform for genomics 
and other systematically acquired data sets 
(http://www.broadinstitute.org/cancer/software/genepattern/); we used compound 
Z-scores instead of gene expression values as inputs, and otherwise standard 
settings.  P-values were determined by randomly permuting mutant and wild-type 
class labels.  For compound set enrichment analysis, we manually curated our 
screened compound list into 141 compound sets of at least 3 compounds 
(Supplemental Table S2 for all 141 set names; individual compounds making up  
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the top scoring sets are listed in Supplemental Table S3).  We used the GSEA 
(Gene Set Enrichment Analysis) module of GenePattern, which calculates a 
weighted Kolmogorov-Smirnov-like statistic (normalized enrichment score, NES) 
for each compound set; this score reflects the extent to which set members 
cause statistically significant, concordant differences in ATP Z-scores between 
mutant vs. wild-type (at HNF4 ) LCLs (18, 22). (See Supporting Information for 
more details.)  P values for each compound setﾒ’s NES score were calculated by 
randomly permuting mutant vs. wild-type HNF4  class assignments 1000 times.   
 
The majority of compound sets were curated based on the World Health 
Organization Anatomical Therapeutic Chemical Classification System (ATC; 
http://www.whocc.no/atc_ddd_index/) that classifies drugs according to 
therapeutic use and chemical properties; additional sets were curated based on 
membership in pathways based on the Kyoto Encyclopedia of Genes and 
Genomes (KEGG; http://www.genome.jp/kegg/) and Ingenuity Pathways Analysis 
(Ingenuity Systems, Redwood City, CA).  
 
  cell ATP and insulin assays  
Murine   cells (MIN6 cells) were cultured in DMEM containing: 25 mM glucose, 
supplemented with 15% FBS (ATCC Manassas, VA), Penicillin (50 I.U./mL), 
Streptomycin (50 µg/mL), and 27.5 µM  ME under humidified conditions of 5%     18
CO2 and 95% air at 37°C. Upon stable infection with shRNA lentiviral infection 
particles, DMEM was supplemented with 1.25 µg/mL puromycin.  
 
All assays were performed in 384-well plates.  For ATP assays, MIN6 cells were 
added to 384-well plates (10,000 cells in 30 µL) in white, solid-bottom 384-well 
plates (Corning 3570) and cultured for 20 hours.  Compound dilutions were pin-
transferred into cells in at least 6 replicates, and incubated with cells for 20 hours 
at 37°C and 5% CO2.  CellTiter-Glo (Promega, Madison, WI) was then performed 
according to manufacturer instructions. Luminescent output was measured using 
an EnVision plate reader (PerkinElmer, Waltham, MA). The Z-scores (Z = 
(meantreatedﾖ–meanDMSO)/standard deviationDMSO) were calculated for each 
compound concentration (in each cell line) using the mean and standard 
deviation of the 42 control DMSO wells found on each plate.  
 
For Glucose Stimulated Insulin Secretion assays, MIN6 cells were seeded at 
9,000 cells/well in black, clear bottom plates (Corning 3712) and cultured in 
DMEM for 24 hours. DMEM was aspirated using an ELx405 microplate washer 
(Biotek, Winooski, VT). All further solutions were prepared in Krebﾒ’s Ringer 
Buffer containing 0.5 % BSA (128 mM NaCl, 5 mM KCl, 2.7 mM CaCl2, 1.2 mM 
MgSO4, 1 mM Na2HPO4, 1.2 mM KH2PO4, 5 mM NaHCO3, buffered with 10 mM 
HEPES, pH 7.4). 30 µL of 2.5 mM D-glucose was added to each well, and 
incubated with cells for 30 minutes at 37°C. The 2.5 mM glucose was aspirated,  
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cells washed once with KRB, and then 30 µL of either 2.5 or 12.5 mM D-glucose 
was added to each well.  Small molecules were pin-transferred using the Cy-Bi 
Well Vario robot, and incubated with cells for two hours at 37°C. At the end of the 
incubation period, cells were pelleted for 5 minutes at 4°C, and 20 µL of the 
secretion medium was collected from each well and frozen at -20°C until 
processing with an Insulin ELISA kit (Alpco Diagnostics, Salem, NH). 
 
Statistical analysis 
When comparing the assay results of two different cell populations (e.g., 
individual compound treatments of mutant vs. wild-type LCLs, or of HNF4 - vs. 
control-knockdown   cells), the two-sided, unpaired Studentﾒ’s t-test was used.  
For compound-set-enrichment-analysis, p-values for enrichment scores were 
calculated by randomly permuting wild-type vs. mutant class labels for the LCLs 
1000 times (see ﾓ“Analysis of interaction screenﾔ” section of Methods for details).  
Two-way ANOVAs were performed to examine the effect of compound treatment 
and HNF4  mutation status on insulin secretion assays. 
 
Additional details on LCL characterization and shRNA knockdown of 
HNF4  in murine   cells are available in the Supporting Information. 
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Figure Legends 
Figure 1. Overview of synthetic genetic interaction approach in patient-derived 
cells.  Small molecules are identified that induce distinct cellular ATP 
measurements in the presence vs. absence of a disease mutation. 
 
Figure 2. Pedigree showing relations among MODY1 individuals screened in this 
study.  Individuals whose lymphoblasts were screened have a number below 
their symbol.  (Numbers correspond to the cell lineﾒ’s designation in the Coriell 
Repository.) The above is a partial pedigree of the previously described MODY1 
family R-W (16). 
 
Figure 3. Identification of disease allele-dependent chemical sensitivities, using 
cells derived from individual patients.  a, Heatmap of small molecules that 
caused the most distinct effects on cellular ATP in mutant vs. wild-type LCLs, i.e., 
with the most positive and most negative S2N from the entire dataset of 3,973 
screened small molecules.  Each row represents a different small molecule, and 
each column is an individual patient-derived LCL sample; heatmap cells reflect 
the Z-score of the ATP assay. b, Distribution of signal-to-noise scores (S2N) for 
all 3,973 screened compounds.   
 
Figure  4.  Compound Set Enrichment Analysis identifies classes of small 
molecules that interact with an HNF4  mutation.  a, Normalized Enrichment  
    27
Scores (NES) from compound set enrichment analysis, plotted against ﾖ–log10P 
(where P-values are determined by randomly permuting wild-type vs. mutant 
class labels 1000 times).  Each data point corresponds to a compound set; 
compound sets are listed in Supplemental Table S2. Dotted line corresponds to 
P = 0.05.  b, Display of output of compound set enrichment analysis.  The 
ﾑ‘linoleic acidﾒ’, ﾑ‘class Ic anti-arrhythmicﾒ’, ﾑ‘K
+-sparing diureticﾒ’, ﾑ‘HMG CoA-
reductase inhibitorﾒ’ and ﾑ‘glucocorticoidsﾒ’ compound sets are among those that 
showed an interaction with HNF4Į in LCLs.  The verticle red-blue bar represents 
the ranked list of 3,973 screened compounds, ranked according to S2N 
(compounds with most positive S2N at the top); horizontal lines indicate where 
each member of the indicated compound set falls within this ranked list. 
Corresponding Normalized Enrichment Score (NES) and permutation P-value for 
the indicated compound set are shown below each bar.  
 
Figure 5.  Many small molecule-disease allele interactions identified in LCLs are 
also preserved in   cells.  For each of the compound sets in Figure 4b, a 
representative compoundﾒ’s induced ATP measurement in   cells is shown; 
dexamethasone, a representative compound from the  ﾑ‘glucocorticoidsﾒ’ set, did 
not interact with HNF4Į in   cells.  White bars: ATP Z-scores in   cells subjected 
to control knockdown; gray bars: Z-scores in cells subjected to HNF4Į 
knockdown. Data are plotted as mean ± standard error of the mean (SEM), and 
are representative results from 2-3 independent experiments.     28
 
Figure 6.  Several small molecules that interact with HNF4Į also enhance insulin 
secretion.  Glucose-stimulated insulin secretion assays were performed on either 
control- (white bars) or HNF4Į-knockdown (gray bars)   cells in the presence of 
the indicated compounds; compound treatments were performed in the presence 
of either 2.5 mM or 12.5 mM glucose.  * = p < 0.05 for comparison of glucose-
stimulated insulin secretion in control- vs. HNF4Į-knockdown   cells (at 12.5 mM 
glucose) in absence of compound treatment. Data are plotted as mean ± SEM, 
and are representative results from 2-3 independent experiments. 
 
  
Compound Set 
Normalized 
Enrichment 
Score (NES) 
P-value   Representative 
compound 
Interaction  
in   cells 
Linoleic acid  -1.73  6.1 x 10
-3 l i n o l e i c   a c i d   + 
 -6 fatty acids  -1.61  0.03  linoleic acid  + 
Oxicam anti-
inflammatories  -1.48  0.026  meloxicam  ﾖ– 
Class Ic 
antiarrhythmics  -1.34  0.12  propafenone  + 
Coxib anti-
inflammatories  1.44  0.035  rofecoxib  ﾖ– 
Potassium-sparing 
diuretics  1.52  0.015  amiloride  + 
Acetic acid anti-
inflammatories  1.53  0.026  diclofenac  ﾖ– 
HMG Co-A reductase 
inhibitors  1.53  7.9 x 10
-3 s i m v a s t a t i n   + 
Imidazole/triazole  
anti-infectives  1.55  0.056  fluconazole  ﾖ– 
Glucocorticoids  1.69  0.028  dexamethasone  ﾖ– 
        
 
Table 1. Compound sets that best discriminate between HNF4  mutant vs. wild-
type LCLs, based on a cellular ATP assay and compound set enrichment 
analysis.  Compound sets shown had the lowest permutation P-values of all the 
compound sets tested (Supplemental Table S2).  Representative compounds 
from each set were tested for their ability to also discriminate between control- 
and HNF4 -knockdown   cells (last column and Fig. 5). 
 